Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4

Leukemia

Volumn 17, Issue 1, 2003, Pages 52-59

  Broggini, M ^a   Marchini, S V ^a   Galliera, E ^a   Borsotti, P ^a   Taraboletti, G ^a   Erba, E ^a   Sironi, M ^a   Jimeno, J ^b   Faircloth, G T ^c   Giavazzi, R ^a   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PHARMAMAR S A   (Spain)

^c PharmaMar USA Inc   (United States)

Author keywords

Apoptosis; Autocrine loop; Leukemia; Marine compounds; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DACTINOMYCIN; DEHYDRODIDEMNIN B; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA STABILITY; TRANSCRIPTION REGULATION;

EID: 0037265805     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402788     Document Type: Article

References (44)

1. Faircloth JG, Rinehart K, Nunez de Castro I, Jimeno J. Dehydrodidemnin B a new marine derived antitumour agent with activity against experimental tumour models. Ann Oncol 1996; 7: 34.
2. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998; 78: 739-744.
3. Urdiales JL, Morata P, Nunez de Castro I, Sanchez-Jimenez F. Anti-proliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102: 31-37.
4. Lobo C, Garcia-Pozo SG, De Castro IN, Alonso FJ. Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 1997; 17: 333-336.
5. Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol 1999; 44: 312-318.
6. Armand JP, Ady-Vago N, Faivre S, Chieze S, Baudin E, Ribrag V, Lecot F, Iglesias L, Lopez-Lazaro L, Guzman C, Jimeno J, Ducreux M, Le Chevalier T, Raymond E. Phase I and pharmacokinetic study of aplidine (APL) given as a 24-hour continuous infusion every other week (q2w) in patients (pts) with solid tumor (ST) and lymphoma (NHL). Proc 37th ASCO Annual Meeting, San Francisco, May 12-15 2001; 20: 120a.
7. Paz-Ares L, Anthony A, Pronk L, Twelves C, Alonso S, Cortes-Funes H, Celli N, Gomez C, Lopez-Lazaro L, Guzman C, Jimeno J, Kaye S. Phase I clinical and pharmacokinetic study of aplidine, a new marine didemnin, administered as a 24-hour infusion weekly. Proc 11th NCI-EORTC-AACR Symposium, Amsterdam, November 7-10 2000; 11: 86.
8. Maroun J, Belanger K, Seymour L, Soulieres D, Charpentier D, Goel R, Stewart D, Tomiak E, Jimeno J, Matthews S. Phase I study of aplidine (APL) in a 1 hour daily infusion x 5 weeks in patients (pts) with solid tumors and low and intermediate grade non Hodgkin's lymphomas: a National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) study. Proc of the European Society for Medical Oncology Meeting, Hamburg, October 13-17 2000; 134.
9. Bowman A, Izquierdo M, Jodrell D, Martinez M, Cicchella B, Jimeno J, Guzman C, Germa-Lluch J, Celli N, Smyth J. Phase I clinical and pharmacokinetic (PK) study of the marine compound aplidine (APL), administered as a 1 hour weekly infusion. Proc 37th ASCO Annual Meeting. San Francisco, May 12-15 2001; 20; 120a.
10. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, Vignati S, Codegoni A, Desiderio AM, Faircloth G, Jimeno J, D'Incalci M. Cell cycle phase perturbations and apoptosis induced by aplidine. Br J Cancer 2002; 86: 1510-1511.
11. Erba E, Ronzoni S, Bergamaschi D, Bassano L, Desiderio AM, Faircloth G, Jimeno J, D'Incalci M. Mechanism of antileukemic activity of Aplidine. Proc Am Assoc Cancer Res 1999; 40: 3.
12. Marchini S, Contegno F, D'Incalci M, Broggini M, Faircloth GT. Gene expression profile in human leukemic MOLT-4 cells treated with the marine compound aplidine. Proc Am Assoc Cancer Res 2000; 41: 833.
13. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35.
14. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-212.
15. Watanabe Y, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Exp Cell Res 1997; 233: 340-349.
16. Watanabe Y, Lee SW, Detmar M, Ajioka I, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997; 14: 2025-2032.
17. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-13316.
18. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59; 728-733.
19. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
20. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999; 54; 567-572.
21. Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 1996; 148: 763-775.
22. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 2000: 34: 386-393.
23. Speirs V, Atkin SL. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999; 80: 898-903.
24. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-624.
25. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468-475.
26. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson C, Mercurio AM. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736-5740.
27. Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434.
28. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001; 98: 10857-10862.
29. von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B, Rosewicz S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000; 119: 1358-1372.
30. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
31. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85: 273-278.
32. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocites. J Natl Cancer Inst 1972; 49: 891-895
33. Vikhanskaya F, Marchini S, Marabese M, Galliera E, Broggini M. P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res 2001; 61: 935-938.
34. Vikhanskaya F, D'Incalci M, Broggini M. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res 2000; 28: 513-519.
35. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
36. Bertolini F, Gobbi A, Rabascio C, Fusetti L, Mancuso P, Conte D, Martinelli G. Autocrine and paracrine effects of vascular endothelial growth factor (VEGF) in lymphoid malignancies. Proc Am Assoc Cancer Res 2000; 41: 776.
37. Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 2000; 60: 2527-2534.
38. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
39. de Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
40. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001 97: 3919-3924.
41. Kay NE, Jelinek DF, Peterson L. Angiogenesis in B-chronic lymphocytic leukemia. Leukemia Res 2001; 25: 709-710.
42. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE., Mesters RM. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
43. Peterson L, Kini AR. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2529.
44. Raymond E, Ady-Vago N, Baudin E, Ribrag V, Faivre S, Lecot F, Wright T, Lopez Lazaro L, Guzman C, Jimeno J, Ducreux M, Chevalier T, Armand JP. A phase I and pharmacokinetic study of aplidine (APL) given as a 24-hour continuous infusion every other week (q2w) in patients (pts) with solid tumor (ST) and lymphoma (NHL). Proc 11th NCI-EORTC-AACR Symposium. Amsterdam, November 7-10 2000; 86 (Abstr. 218).